Elpamotide
Elpamotide is an epitope peptide derived from VEGFR2. Elpamotide induces cytotoxic T lymphocytes (CTLs) to kill VEGFR2-expressing endothelial cells. Elpamotide has potential immunostimulatory and antineoplastic activities. Elpamotide can be used in the research of cancer, such as pancreatic cancer[1][2].
Product Specifications
CAS Number
673478-49-4
UNSPSC
12352209
Target
VEGFR
Type
Peptides
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/elpamotide.html
Solubility
10 mM in DMSO
Smiles
N=C(N)NCCC[C@H](N)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](C(C)C)C(N2[C@@H](CCC2)C(N[C@@H](CC(O)=O)C(NCC(N[C@@H](CC(N)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@H](C(O)=O)[C@@H](C)CC)=O)=O)=O)=O)=O)=O)=O)=O
Molecular Formula
C47H76N16O13
Molecular Weight
1073.21
References & Citations
[1]Yamaue H, et al. Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study. Cancer Sci. 2015 Jul;106 (7) :883-90. |[2]Wada S, et al. Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res. 2005 Jun 1;65 (11) :4939-46.
Shipping Conditions
Room temperature
Scientific Category
Peptides
Clinical Information
Phase 2
Isoform
VEGFR2/KDR/Flk-1
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
